The central conceptual move is a sharp separation between what is observed and what is inferred. For each unit i, the method defines a parameter-conditional tail functional, the probability that a replicated count drawn from the fitted model would exceed a threshold, given that unit’s covariates. Averaging this functional over the posterior distribution of the model parameters yields the posterior predictive exceedance probability, the quantity used for ranking and calibration. A large realized count, the paper stresses, is informative but is not itself the inferential target: a person with moderate observed utilization may still carry high replicated-count risk once health status, insurance characteristics, and model uncertainty are accounted for. Conversely, an isolated spike in the data may reflect contamination rather than genuine tail risk.

The working model is a negative binomial regression, a standard choice for overdispersed counts because it relaxes the restrictive variance assumption of the Poisson model while retaining an interpretable conditional mean. The robustness, however, comes from an additional layer. Each observation receives a positive latent scale that locally inflates or deflates its mean, drawn from a two-component mixture: a point mass at one, which preserves the ordinary negative binomial baseline, and a Beta-prime slab with substantial mass near zero and a polynomially decaying right tail. This construction, adapted from recent robust Bayesian count modeling, allows excess zeros and isolated large counts to be absorbed by the local scale rather than forcing them to distort the regression coefficients or the fitted tail probabilities. In effect, unusual observations are quarantined instead of being allowed to hijack the analysis.

The theory is deliberately framed for the realistic case where the model is wrong. Rather than assuming the data follow the negative binomial family exactly, the contraction results are stated around the Kullback–Leibler projection of the true law onto the working family — a pseudo-true parameter that represents the best available approximation. Following the classical misspecification perspective of Berk and of Kleijn and van der Vaart, the posterior is shown to concentrate near this projection, and a Lipschitz transfer argument shows that concentration in parameters carries over to uniform concentration of the exceedance functionals themselves. Pinsker’s inequality then bounds the error between true tail probabilities and the working-model targets by the Kullback–Leibler discrepancy, giving a quantitative account of how much misspecification can distort screening decisions.

Discovery, as opposed to ranking, is handled by a separate layer built on e-values. Posterior thresholding of the evidence probability — the posterior probability that a unit’s exceedance probability exceeds a chosen level gamma — is a natural local Bayes rule under a loss function penalizing false positives and false negatives, but it does not by itself control the false discovery rate across many simultaneous tests. The paper therefore converts posterior odds into Bayes factors and submits them to the e-BH procedure of Wang and Ramdas, which controls the false discovery rate under arbitrary dependence among the test statistics. The validity of this step is stated with unusual care: under the Bayes-marginal null induced by the same hierarchical model, posterior odds are Bayes factors and hence valid e-values with null expectation at most one. Under a mere working-model interpretation, the same quantities are evidence scores unless calibrated, and the author includes an approximate-validity result in which the FDR bound is inflated by a calibration error term. This honesty avoids the common pitfall of treating a parametric Bayesian fit as automatically producing model-free frequentist guarantees.

Computation is provided at three levels of fidelity. A reference Markov chain Monte Carlo sampler uses Pólya–Gamma augmentation to update the regression coefficients in a single Gaussian block, with slice sampling and adaptive random-walk Metropolis steps for the latent scales, dispersion parameter, and slab hyperparameters; convergence is monitored with rank-normalized split R-hat statistics and effective sample size thresholds. For large datasets and repeated simulations, a bounded-influence iteratively reweighted least squares Laplace approximation downweights extreme Pearson residuals and high-leverage observations, producing a Gaussian approximate posterior from which the exceedance summaries can be drawn directly. A mean-field variational option offers fast screening. A theorem bounds the error of any such approximation: the discrepancy between exact and approximate posterior exceedance probabilities is controlled by the total variation distance between the two posteriors, which in turn is bounded by a square root of the Kullback–Leibler divergence between them.

The simulation evidence demonstrates a clear and quantified robustness–efficiency tradeoff. Under clean data, the ordinary negative binomial fit is slightly more efficient, with marginally higher true positive rates and smaller calibration error. Under contamination — engineered as a mixture of near-zero structural zeros and heavy upper-tail multiplicative contamination at rates of ten and twenty percent — the picture reverses dramatically. At ten percent contamination, the robust procedure cuts the false discovery proportion from 0.029 to 0.002 and halves the calibration error metrics. At twenty percent contamination and a sample size of one thousand, the naive method’s false discovery proportion climbs to roughly 0.099 while the robust method holds near 0.004, with expected calibration error of about 0.090 versus 0.040. A more aggressive variant using Tukey’s biweight weights proves most conservative of all, illustrating that the degree of robustness tunes a power–conservatism dial rather than dominating uniformly. Reliability plots confirm that the robust fit tracks the clean oracle tail probabilities across the range, while the naive fit inflates the upper bins under contamination.

The real-data application turns to the RAND Health Insurance Experiment, a classic dataset of 20,190 observations on outpatient physician visits, adjusted for insurance plan, income, physical limitation, chronic disease burden, and self-rated health. Screening for individuals whose replicated visit count exceeds eight visits, with a discovery level of 0.3 and e-BH applied at a false discovery rate of 0.1, both fits select subgroups whose observed exceedance rates — 0.339 for the naive fit and 0.315 for the robust fit — tower over the full-sample rate of 0.071. The robust fit selects a somewhat larger set while shrinking tail probabilities more aggressively over most of the sample, yet still assigns high risk to individuals with severe health profiles. A training–holdout split with 2,000 posterior predictive replicates showed the observed zero rate falling at the edge of its predictive interval, while the mean count and exceedance rate exceeded theirs — a candid indication that the working model remains conservative in the upper tail and not fully distributionally adequate.

Perhaps the most practically important feature of the paper is its insistence on reporting three distinct outputs separately: calibrated tail-risk rankings, posterior evidence scores, and multiplicity-controlled discovery sets. Some individuals selected by the procedure did not actually exceed eight visits in the observed record, which the author presents as expected behavior rather than a failure — the method targets replicated-count risk conditional on covariates and model uncertainty, not the realized indicator alone. The selected individuals are characterized by physical limitation and high chronic-disease burden, exactly the covariate profiles one would associate with latent high utilization. The paper also warns against a subtle computational trap: e-value caps that are too small can mechanically prevent the e-BH procedure from making any rejections, so decision steps must use uncapped Bayes factors or caps compatible with the rejection thresholds.

Taken together, the study offers a transparent template for combining Bayesian tail modeling, robust count regression, and e-value-based multiple testing in settings where the data are messy, overdispersed, and possibly contaminated. The author suggests that future work may extend the framework to richer dependence structures, more flexible count families, and sequential e-value methods for online monitoring — a natural next step for applications ranging from epidemiological surveillance to industrial quality control, where the question is not merely how many events occur, but who is genuinely at risk of crossing the line.

Subject of Research: Robust Bayesian exceedance screening and false discovery rate control for overdispersed count data

Article Title: Robust Bayesian exceedance screening for count data

Article References: Sadeghkhani, A. (2026). Robust Bayesian exceedance screening for count data. International Journal of Data Science and Analytics, 22(1), Article 323. https://doi.org/10.1007/s41060-026-01312-5

Image Credits: AI Generated

DOI: 10.1007/s41060-026-01312-5

Keywords: Bayesian inference, exceedance probability, e-values, negative binomial regression, robust statistics, false discovery rate, count data, Kullback–Leibler projection, RAND Health Insurance Experiment, multiple testing, posterior contraction, health utilization

The critique, authored by Shubhendu Mohanty, Adarsh Jyoti Lakra, Hima Bindu Mantravadi, Prerna Uniyal and Dhanya Dedeepya, does not dispute the value of the underlying cohort. Assembling nearly a hundred well-characterized patients with two rare vasculitides, imaged to a common protocol and tracked over years, is genuinely difficult work, and the descriptive account of vascular distribution and treatment patterns stands as a useful contribution to the literature. The objection is narrower and more technical: it concerns what kind of question this particular study design is capable of answering, and whether the answer the authors reached was baked into the study before the first patient was enrolled.

The heart of the problem lies in the 2022 classification criteria from the American College of Rheumatology and the European Alliance of Associations for Rheumatology, which were used to allocate patients to the two diagnostic groups. Classification criteria are, by design, tools built to discriminate between named diseases. They are constructed from clinical and imaging features known to separate the conditions, and they are validated for that discriminating purpose. When a study then compares the groups on those same features and reports the differences as findings, the analysis becomes circular. The classifier and the outcome are the same variable, and the result is a foregone conclusion dressed in the language of discovery.

Age offers the clearest illustration of this circularity. The Takayasu criteria require disease onset at or below 60 years of age, while the giant cell arteritis criteria require patients to be 50 or older. The Italian study reported a median age of 33 in the Takayasu group against 76 in the giant cell arteritis group, with a p-value below 0.001. But as the commentators point out, this striking difference simply restates the entry rule. No patient over 60 could appear in the Takayasu group, and few under 50 could appear in the giant cell arteritis group. Reporting the age gap as a distinguishing feature of the two diseases adds no new biological information; it merely echoes the arithmetic of the classification scheme.

Vascular distribution presents a more consequential version of the same problem. The study’s methods state explicitly that the differentiation of cranial giant cell arteritis from its large-vessel form, and from Takayasu arteritis, was based on angiographic assessment. Yet the results then compare angiographic vascular distribution between the groups and report involvement of the axillary arteries, the aortic arch, the mesenteric vessels and the renal arteries as findings that distinguish the diseases. Polymyalgia rheumatica, which was present in 37.8 percent of the giant cell arteritis group and in none of the Takayasu group, falls into the same category, because it is a recognized component of the giant cell arteritis phenotype that informs the diagnosis in the first place. In each case, the feature that appears to separate the groups is the feature that was used to separate them.

Crucially, the commentators are not arguing that Takayasu arteritis and giant cell arteritis are the same disease. Their claim is epistemological rather than clinical: a cohort assembled through classification criteria cannot adjudicate whether the two entities are distinct, because the criteria were engineered to make them distinct. The features that could genuinely settle the question are precisely the ones the criteria do not use, and the Italian study actually measured several of them. Erythrocyte sedimentation rate and C-reactive protein, the two classic inflammatory markers, showed no significant difference between the groups, with p-values of 0.722 and 0.448 respectively. Neurologic and pulmonary manifestations likewise did not differ, and the long-term remission rate was reported as not significantly different in the abstract. An analysis restricted to these criteria-independent variables, the commentators suggest, would constitute a real test of the distinctness question, and would arguably make a more interesting paper.

The critique raises a second, independent statistical concern: the sheer number of comparisons. Across Tables 1, 2 and 3, the original study performed roughly thirty, eleven and ten statistical tests respectively, all evaluated at a significance threshold of 0.05 with no adjustment for multiple testing. At that volume of testing, chance alone guarantees that two or three findings will cross the significance threshold even if no true differences exist. Several of the differences that survived into the paper’s conclusion were marginal: dermatologic involvement at p equals 0.04, chronic liver disease at p equals 0.02, axillary artery involvement at p equals 0.02, and low-dose glucocorticoid use at p equals 0.04. The commentators note that Fisher’s exact test, which the authors appropriately chose for the sparse data, validates each individual test but does nothing to address the multiplicity problem. Their proposed remedy is straightforward: designate a small number of prespecified comparisons as primary, and label everything else exploratory.

A third concern involves confounding by referral pattern, a problem the original authors themselves acknowledged in their limitations section. One of the three participating centers is a regional tertiary referral center for Takayasu arteritis, which the authors offered as an explanation for the imbalance in group sizes. But the consequences of that arrangement extend well beyond group size. A referral center concentrates severe and refractory disease, so the Takayasu group was enriched for exactly the patients most likely to receive aggressive treatment. The study reported high-dose glucocorticoid use in 59.3 percent of Takayasu patients against 18.9 percent of giant cell arteritis patients, combination therapy with glucocorticoids plus immunosuppressants in 86.4 percent against 51.4 percent, and interventional vascular procedures in 25.4 percent against 5.4 percent. These figures, the commentators argue, reflect differences between two differently recruited populations at least as much as differences between two diseases, and the conclusion that the conditions respond differently to therapy does not follow from them.

The comment also catalogs a series of numerical inconsistencies that the authors are asked to reconcile at proof stage. The abstract reports the p-value for time from symptom onset to diagnosis as 0.025, while Table 1 and the results text give 0.029. The caption to Table 3 describes a cohort of 84 patients, although the study comprises 96. The subclavian artery row of Table 2 lists the giant cell arteritis proportion as 35140, presumably a typographical error for 35.14 percent. And the proportion of patients followed for at least 60 months appears as 72 percent in the abstract and discussion but 75 percent in the methods. None of these discrepancies is individually decisive, but together they underscore the importance of careful proofreading in studies that will inform clinical classification.

The broader lesson extends well beyond this single cohort. Classification criteria are indispensable tools for enrolling homogeneous patient groups into research studies and for standardizing clinical communication, but they are diagnostic heuristics, not ground truth. When researchers compare groups defined by such criteria on the variables that constitute them, they risk converting a definitional artifact into a purported biological finding. The commentators close with a constructive proposal: the Italian cohort remains a valuable resource, and a comparison restricted to criteria-independent features, governed by a prespecified analysis plan, would allow the data to speak to the question the study set out to answer. Until such an analysis is performed, the claim that Takayasu arteritis and giant cell arteritis require fundamentally different approaches remains plausible, but unproven by this evidence, a distinction that matters for the clinicians treating these rare and potentially devastating diseases of the large arteries.

Subject of Research: Methodological critique of a cross-sectional comparison of Takayasu arteritis and giant cell arteritis

Article Title: Comment on “Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross‐Sectional Study of 96 Italian Patients”

Article References: Mohanty, S., Lakra, A. J., Mantravadi, H. B., Uniyal, P., & Dedeepya, D. (2026). Comment on “Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross‐Sectional Study of 96 Italian Patients”. Immunity, Inflammation and Disease, 14(9), Article e70513. https://doi.org/10.1002/iid3.70513

Image Credits: AI Generated

DOI: 10.1002/iid3.70513

Keywords: Takayasu arteritis, giant cell arteritis, vasculitis, classification criteria, ACR/EULAR 2022, circular reasoning, multiple testing, referral bias, rheumatology, statistical methodology, large-vessel vasculitis, epidemiology

The mathematical stage for this work is the Gaussian graphical model, a workhorse of high-dimensional statistics in which each node represents a random variable and an edge indicates that two variables are conditionally dependent given all the others. In genetics, such a graph might capture regulatory relationships among thousands of genes; in neuroscience, it can summarize which brain regions coordinate their activity at rest. When researchers collect samples from two populations, say healthy individuals and patients, the natural scientific question is not whether the two graphs are different in some vague, global sense, but exactly which edges differ. This is the domain of differential network analysis, and it has been hampered by a stubborn technical constraint: nearly every existing method assumes that the base graphs themselves are sparse, meaning each node connects to only a handful of neighbors.

That sparsity assumption is often unrealistic. Biological and social networks can be densely connected, with each node linked to many others, while the true differences between two conditions remain concentrated in a small subset of edges. Methods built for sparse graphs can break down entirely in this regime, producing floods of spurious discoveries or missing genuine signals altogether. DNetEx departs from this tradition by requiring only that the differential edges, the connections that actually change between the two models, be few, while placing essentially no restrictions on the density or structure of the base graphs. According to the authors’ theoretical analysis, this makes the framework substantially more general than prior approaches.

The method’s statistical core is a guarantee of false discovery rate control, one of the most celebrated ideas in modern multiple testing. When a procedure tests thousands of hypotheses simultaneously, as happens when every possible edge in a graph is a candidate for change, some false positives are inevitable. The false discovery rate, introduced by Yoav Benjamini and Yosef Hochberg in 1995, measures the expected proportion of false positives among the declared discoveries, and keeping it below a user-chosen threshold is what separates trustworthy exploratory science from an undisciplined laundry list of findings. DNetEx is proven, under mild conditions, to control this rate asymptotically, meaning that as sample sizes grow, the fraction of reported edges that are genuine changes remains reliably high.

Technically, the framework weaves together three ingredients. First, sample splitting divides the available data, with one portion used to screen and rank candidate differential edges and the remainder reserved for independent statistical validation, a strategy that avoids the circularity of testing hypotheses on the same data used to generate them. Second, a screening mechanism prunes the enormous space of possible edges down to a manageable candidate set, slashing computational cost while a tunable parameter lets practitioners balance statistical power against runtime. Third, validation relies on e-values and the e-BH procedure, a modern alternative to traditional p-values that has gained traction in fields ranging from quantum cryptography to clinical trials. The method constructs mirror statistics whose null distributions are symmetric about zero, and the proof that the resulting procedure is a valid instance of e-BH testing leans on an elegant supermartingale argument adapted from earlier work on knockoffs and data splitting.

The theoretical scaffolding is backed by theorems establishing joint asymptotic normality of the quadratic forms underlying the test statistics, derived through Taylor expansions of the sample covariance inverse, Lyapunov central limit arguments, and careful control of remainder terms using operator norm bounds and Weyl’s inequality. In extensive experiments on synthetic data, DNetEx maintained accurate false discovery rate control and strong detection power, including settings where competing approaches failed to control the rate at all. Supplementary analyses pushed the dimension to a thousand variables and confirmed that the method remains computationally tractable and statistically sound, even as the number of possible edges grows quadratically with dimension and sparse differential structure becomes ever harder to recover.

The sensitivity analyses reveal a method with tunable, well-understood knobs. Increasing the screening parameter enlarges the candidate set and initially boosts power, but beyond a moderate point the gains flatten while computational cost keeps climbing. Adjusting the sample-splitting ratio shows that starving the screening stage of data erodes the quality of candidate selection, while over-allocating samples to validation wastes information. Randomness in the split does introduce some variability in which edges get detected on any single run, an honest limitation the authors acknowledge, though average false discovery proportions remained controlled across all tested configurations, and more robust splitting strategies are flagged as a promising direction for future work.

The most striking demonstration, however, came from real brain imaging data. Applying DNetEx to resting-state functional MRI connectivity from the Autism Brain Imaging Data Exchange, the team compared neurotypical individuals with people on the autism spectrum. Where competing methods detected no differential edges whatsoever, DNetEx identified eighteen connections between regions of the Dosenbach atlas whose connectivity differed between groups. Crucially, many of these edges involve regions long implicated in autism research, including the temporoparietal junction, the ventromedial prefrontal cortex, the insula, and the precuneus, areas tied to face expression processing, theory of mind, and the sense of self. The method recovered these biologically plausible patterns without any domain-specific priors, relying purely on statistical structure.

For the autism research community, the result is more than a technical curiosity. Altered functional connectivity has been a central, and sometimes contentious, theme in neuroimaging studies of the spectrum, with reports of both hyperconnectivity and reduced connectivity across various cortical networks. A method that can rigorously certify which specific connections differ, while provably limiting false discoveries, offers a path toward more reproducible findings in a field where small samples and thousands of simultaneous tests have fueled concerns about reliability. The same logic applies directly to genomics, where differential network analysis has been proposed as a way to trace how disease rewires gene regulatory circuits, and to domains as varied as finance and anomaly detection in streaming data.

The researchers have released their source code publicly on GitHub, allowing other teams to apply the framework and reproduce every experimental result reported in the paper. As scientific datasets grow in size and complexity, tools that combine rigorous error control with genuine scalability become not just convenient but essential. DNetEx suggests that the next generation of network comparison methods can be both statistically honest and computationally practical, and that when the mathematics is done right, the tangled wiring diagrams of the brain and the cell may finally begin giving up their secrets, one verified edge at a time.

Subject of Research: FDR-controlled differential network analysis between Gaussian graphical models

Article Title: DNetEx: FDR-controlled differential network analysis for knowledge discovery from graphs

Article References: Nikahd, M., Emrani, A., & Motahari, S. A. (2026). DNetEx: FDR-controlled differential network analysis for knowledge discovery from graphs. Data Mining and Knowledge Discovery, 40(6), Article 97. https://doi.org/10.1007/s10618-026-01245-4

Image Credits: AI Generated

DOI: 10.1007/s10618-026-01245-4

Keywords: differential network analysis, Gaussian graphical models, false discovery rate, e-values, graph structure learning, brain connectivity, autism spectrum disorder, fMRI, multiple testing, high-dimensional statistics, knowledge discovery, machine learning